Figure 2.

Example results for the predicted response to NAT regimens for 1 patient (patient 4) whose standard-of-care regimen consisted of combination doxorubicin and cyclophosphamide every 3 weeks for 12 weeks (4 total cycles). The figure depicts anatomical images of a central slice of the breast overlaid with the total tumor cellularity in color. While there is not an exact match between the patient's actual scan 3 data (panel a) and the prediction for the standard regimen (i.e., the standard-of-care regimen the patient actually received, panel b), the percent differences between the predicted and measured tumor response for the standard-of-care regimen are 1%, 16%, and 1% for total cellularity, volume, and longest axis. The total cellularity predicted for 2 alternative regimens are also depicted: 1/3 of a dose every week (panel c), and 1/21 of a dose administered daily (panel d). (Note: each alternative regimen had the same total drug over the treatment period as the standard-of-care regimen). Across all the regimens, the model predicted the greatest tumor cell reduction when the daily dose regimen was implemented. Compared to the standard-of-care regimen, the model predicted that the daily dose regimen would result in an additional 45% reduction in total tumor cellularity.